Zenith Capital (Zenith Capital) EV-to-Revenue : (As of Jun. 04, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zenith Capital's enterprise value is $18.68 Mil. Zenith Capital does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Zenith Capital's EV-to-Revenue at this moment.

The historical rank and industry rank for Zenith Capital's EV-to-Revenue or its related term are showing as below:

ZHCLF's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.075
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-04), Zenith Capital's stock price is $0.13. Zenith Capital does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Zenith Capital's PS Ratio at this moment.

Zenith Capital EV-to-Revenue Historical Data

The historical data trend for Zenith Capital's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EV-to-Revenue Chart

Zenith Capital Annual Data

Trend

EV-to-Revenue

Zenith Capital Quarterly Data

EV-to-Revenue

Competitive Comparison of Zenith Capital's EV-to-Revenue

For the Biotechnology subindustry, Zenith Capital's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zenith Capital's EV-to-Revenue falls into.

Zenith Capital EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Zenith Capital's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	18.676	/
	=

Zenith Capital (OTCPK:ZHCLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Zenith Capital's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.13	/
	=

Zenith Capital EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines